Evidence Hub

High Prevalence Of Vitamin D Deficiency And Secondary Hyperparathyroidism In Irish Patients With Acute Hip Fracture

Michelle O'Dwyer, Amy Lynch, Aisling Carroll, Matthew Kavanagh, Kenneth McSherry, N. Maher, N. Fallon, C. O'Carroll et al.

Age and Ageing, 2025

149 participants

Abstract

Vitamin D deficiency can cause secondary hyperparathyroidism (SHPT) which results in bone loss, particularly at cortical sites such as neck of femur, distal radius and humerus. Hip fracture patients have a higher prevalence of frailty and are at greater risk for vitamin D deficiency (25(OH)D< 30 nmol/l) or insufficiency (25(OH)D 30-49.9 nmol/l). Vitamin D replete status is also important in preventing hypocalcaemia in patients receiving zoledronate. We aimed to determine the prevalence of low vitamin D status and SHPT in acute hip fractures patients at our hospital.

Data on demographics, vitamin D status and PTH levels were recorded on acute hip fracture patients (aged >65 years) over a 12 month period from April 2023. A serum PTH level above 65 pg/ml in the presence of normal or low serum calcium was considered to represent SHPT. We explored for prevalence of vitamin D deficiency/insufficiency and predictors of SHPT in regression analysis.

149 patients were reviewed, mean age 82.5 years, 76.2% female. 22.8 % were vitamin D deficient and 16.1% had vitamin D insufficiency. Overall, 38.9% had serum 25(OH)D below 50 nmol/l. SHPT occurred in 22.9% and was predicted by low vitamin D status (<50 nmol/l, P=0.011) but not by age or gender.

Roughly 25% with hip fractures had vitamin D deficiency and about 40% suboptimal levels. Importantly, one in four also had SHPT. Vitamin D levels should be >50 nmol/l prior to zoledronic acid therapy. However, vitamin D results during the acute…

Read the paper

Related studies

Go deeper in Evidence Hub

Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.

Open this study Sign up free